Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHL NASDAQ:ADVM NASDAQ:APTO NASDAQ:INMB NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25744,051 shsN/AADVMAdverum Biotechnologies$3.02-1.6%$2.82$1.78▼$8.56$64.42M0.9274,145 shs28,976 shsAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsINMBINmune Bio$1.99+1.0%$2.34$1.71▼$11.64$52.37M1.03814,990 shs468,384 shsTCRXTScan Therapeutics$1.72+1.8%$1.80$1.02▼$6.23$95.90M1216,352 shs190,725 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+104.76%ADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%APTOAptose Biosciences0.00%0.00%0.00%0.00%-84.75%INMBINmune Bio-1.99%+8.84%-22.13%-71.32%-63.92%TCRXTScan Therapeutics-3.98%-10.11%-6.11%+9.74%-70.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25744,051 shsN/AADVMAdverum Biotechnologies$3.02-1.6%$2.82$1.78▼$8.56$64.42M0.9274,145 shs28,976 shsAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsINMBINmune Bio$1.99+1.0%$2.34$1.71▼$11.64$52.37M1.03814,990 shs468,384 shsTCRXTScan Therapeutics$1.72+1.8%$1.80$1.02▼$6.23$95.90M1216,352 shs190,725 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+104.76%ADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%APTOAptose Biosciences0.00%0.00%0.00%0.00%-84.75%INMBINmune Bio-1.99%+8.84%-22.13%-71.32%-63.92%TCRXTScan Therapeutics-3.98%-10.11%-6.11%+9.74%-70.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AADVMAdverum Biotechnologies 2.75Moderate Buy$19.75553.97% UpsideAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideINMBINmune Bio 2.57Moderate Buy$18.40824.62% UpsideTCRXTScan Therapeutics 3.00Buy$7.80353.49% UpsideCurrent Analyst Ratings BreakdownLatest ADVM, TCRX, ACHL, APTO, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.008/12/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.007/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AADVMAdverum Biotechnologies$1M63.36N/AN/A$3.40 per share0.89APTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AINMBINmune Bio$10K5,289.42N/AN/A$1.45 per share1.37TCRXTScan Therapeutics$2.82M34.61N/AN/A$4.26 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%N/AADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)APTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)Latest ADVM, TCRX, ACHL, APTO, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/12/2025Q2 2025TCRXTScan Therapeutics-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAPTOAptose BiosciencesN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04ADVMAdverum BiotechnologiesN/A1.541.54APTOAptose BiosciencesN/A1.051.05INMBINmune BioN/A4.204.20TCRXTScan Therapeutics0.187.067.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%ADVMAdverum Biotechnologies48.17%APTOAptose Biosciences26.62%INMBINmune Bio12.72%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%ADVMAdverum Biotechnologies6.00%APTOAptose Biosciences1.33%INMBINmune Bio35.70%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataINMBINmune Bio1026.58 million17.09 millionOptionableTCRXTScan Therapeutics10056.75 million54.28 millionNot OptionableADVM, TCRX, ACHL, APTO, and INMB HeadlinesRecent News About These CompaniesEcoR1 Capital LLC Sells 4,337,167 Shares of TScan Therapeutics, Inc. $TCRXSeptember 6, 2025 | marketbeat.comTScan Therapeutics, Inc. $TCRX Shares Bought by Checkpoint Capital L.P.September 6, 2025 | marketbeat.comBVF Inc. IL Purchases 1,900,000 Shares of TScan Therapeutics, Inc. $TCRXSeptember 5, 2025 | marketbeat.comTScan Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by BrokeragesAugust 30, 2025 | marketbeat.comTocqueville Asset Management L.P. Sells 233,870 Shares of TScan Therapeutics, Inc. $TCRXAugust 21, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for TCRX FY2025 Earnings?August 19, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TCRX FY2025 EarningsAugust 17, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for TCRX Q3 Earnings?August 17, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for TScan TherapeuticsAugust 17, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash WiselyAugust 15, 2025 | finance.yahoo.comTScan Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comTScan Therapeutics reports Q2 EPS (28c), consensus (32c)August 12, 2025 | msn.comTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comTScan Therapeutics Elects New Directors at Annual MeetingJuly 27, 2025 | theglobeandmail.comOne TScan Therapeutics Insider Raised Stake By 18% In Previous YearJuly 19, 2025 | finance.yahoo.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9, 2025 | investing.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADVM, TCRX, ACHL, APTO, and INMB Company DescriptionsAchilles Therapeutics NASDAQ:ACHLAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Adverum Biotechnologies NASDAQ:ADVM$3.02 -0.05 (-1.63%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.01 (+0.33%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Aptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.INmune Bio NASDAQ:INMB$1.99 +0.02 (+1.02%) Closing price 04:00 PM EasternExtended Trading$1.98 0.00 (-0.25%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.TScan Therapeutics NASDAQ:TCRX$1.72 +0.03 (+1.78%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.01 (+0.58%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
